REGULATORY
    LDP Flags 80% Generic Target for All Prefectures: Honebuto Debate
    June 11, 2021
    The ruling Liberal Democratic Party (LDP) has raised a red flag for the proposed new 80% target for generic drugs in all Japanese prefectures, as some lawmakers voiced concerns about the marred credibility of these…

    LATEST

    PhRMA Posts Its Position on Japan CEA Scheme on Website
    June 11, 2021
    The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 10 posted the overview of the Japanese cost-effectiveness assessment (CEA) system on its Japan website, reiterating its position against its application on reimbursement decisions.Through this…
    Eisai’s Akana Re-Elected as FPMAJ’s Drug Pricing Chief
    June 11, 2021
    The Federation of Pharmaceutical Manufacturers’ Associations of Japan’s (FPMAJ) drug pricing committee on June 10 re-elected Masatomi Akana, chief government relations officer at Eisai, as its chairman for a new two-year term.“Discussions towards the next drug pricing revision (in April…
    Astellas, Otsuka, Meiji Joining Workplace Vaccination Campaign
    June 11, 2021
    The Japanese government’s workplace vaccination initiative for COVID-19 is drawing a growing list of companies from the pharmaceutical sector, with Astellas Pharma and the Otsuka group among the latest to reveal their intentions to take part in the campaign.Astellas submitted…

    COMMENTARY

    Battle Looming over 2% Adjustment Rate as New Honebuto Paper Nears Completion
    By Yoshinori Sagehashi

    The government is in the process of finalizing the 2021 Basic Policy for Economic and Fiscal Management and Reform (honebuto). This year’s policy will have a higher importance than previous ones because the drastic reforms of the drug pricing system…

    COLUMN

    Pricing Reform in Japan - How Manufacturers Can Ensure Fair Compensation for Value and Innovation
    By Eric Persoff

    Last month, when discussing how life science manufacturers should react to the evolving pricing environment in Japan, I wrote about how manufacturers should align with stakeholders in government and the medical community on fair compensation for innovative, value creating, biopharmaceutical…

    FY2021 Drug Maker Employment Survey

    Drug Makers’ Female Manager Ratio at 12.5%; Major Gap between Japan, Foreign Players

    The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

    INTERVIEW

    From Treatment to Prevention, Top Expert on AD Research, Aducanumab and Its Implications - 2
    By Yoshinori Sagehashi

    Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

    FY2020 Drug Pricing Reform

    Japan Panel Hammers Out FY2020 Drug Pricing Reform

    Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA